Navigation Links
Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division

LAWRENCEVILLE, N.J., Feb. 8 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Michael H. Richardson has joined the company as Vice President, Commercial Operations for the newly formed Orphan Drug Business Unit. Donald A. Fishbein assumes the same role for the Ophthalmic Business Unit. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

Mr. Richardson holds responsibility of the company's orphan drug portfolio, which includes well-established specialty pharmaceuticals treating a range of rare and life-threatening conditions (Mephyton®, Edecrin®, Sodium Edecrin®, Cuprimine®, Syprine®, Demser®).  

Mr. Richardson possesses nearly 20 years of experience in pharmaceutical marketing, sales, product planning and business development. Prior to joining Aton, he was a Group Director of Marketing and Senior Director of Worldwide Product Planning for Cephalon. In those roles, Mr. Richardson was responsible for the successful launch of multiple products.

"With both product and corporate management experience, Michael Richardson brings tremendous commercial leadership to Aton Pharma," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is well rounded in all aspects of pharmaceutical marketing and preparing new products for launch. This experience will provide tremendous value to the company as we expand our orphan drug portfolio."

Prior to Cephalon, Mr. Richardson was a Director of Global Strategic Marketing at Johnson & Johnson where he worked on optimizing the life cycle of several strategic products. Also at Johnson & Johnson he served in New Product Planning. Prior to Johnson & Johnson, Mr. Richardson was in Sales for Merck & Co., Inc. He holds a B.A. degree in Chemistry from West Virginia University and a M.B.A. from the Fuqua School of Business at Duke University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see

SOURCE Aton Pharma, Inc.



SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
2. Octapharma Accepting Applications for Research Grants Through March 31
3. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
4. Possible pharmacological target(s) identified in pediatric OSA
5. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
6. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
7. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
8. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
9. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
10. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
11. Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University announced Tuesday (Oct. ... Initiative aimed at enhancing Purdue’s life sciences research and graduate education. The initiative ... , The investment will result in cohesive efforts across several colleges and is ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ProText Kinetic ... X . With ProText Kinetic Panel, users can create energetic text animations in any ... preset into the Final Cut Pro X timeline and stylize the text. With intuitive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing product review ... "Publish Academy" training course . Singal's new program, in which he reveals his ... around the Internet are weighing in with reviews. , "Considering the fairly high ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology: